Money, cubes and business card with inscription – Skazovd's Aristocrat dividend via Shutterstock
In uncertain times, dividend income is more than just a strategy;It helps you sleep better at night.The key is to know which ones to choose and when to buy. As for what dividend stocks to buy, I like companies with a long history of increasing their dividends, such as the dividend aristocrats.
Difidend nobles are S&P 500 listed companies that have increased their dividends for at least all the past 25 years.
In terms of answering the question, “When do I buy?” It was said that time in the market beat market timing over the long journey, because buying at the wrong time can lead to earnings erosion.
So, with that out of the way, I thought of looking for some quality dividend aristocrats that locate themselves for a break in CH3'25.
Using Barchart's stock screenser, I selected the following filters to get my results:
The number of analysts: At least 12 analysts. A high number of analysts reflect a better rating consensus.
Current analyst score: Moderate to buy strong.
Signal Buy/Sell/Capture Generally: Buy. It filters which stocks have a purchase signal.
General Opinion Address: Average to the highest 1%. It states that the signal direction is strengthening.
The strength of general opinion: Average – 1%highest. It is a long -term measure of strength. Stronger strength means less volatility, and that's what we're looking for.
Watchman: Aristocrat dividend.
I ran these filters and got 6 aristocrat dividend:
Of course, we want to find the most moving up -up dividend aristocrats, so I sorted out the results based on the strength of the general view.
Let's start this list, starting with number one:
Cardinal Health is a drug distributor, healthcare services, and products company. The company specializes in providing customized solutions for various health needs in over 30 countries, including more than 90% of US hospitals. Cardinal Health operates under two main segments: pharmaceutical and specialist solutions, and world -eag medical products and distribution.
The company's latest financial issues identified sales of $ 730 million, up 98% from the previous year. His net income also increased 93.9% year -on -year to $ 508 million.
Cardinal Health is an aristocrat dividend that has increased its dividends for 29 consecutive years. It pays forward an annual dividend of $ 2.04 per share, which translates into a product of approximately 1.23%. That said, 14 analysts rank a strong purchase to the CAH.
Barchart's view suggests that CAH is a 100% overall purchase, with the highest current strength score of “top 1%,” and its strongest current direction. Together, investors have the opportunity to take advantage of a potentially bullish run.
The second aristocrat dividend on the list is international business machines. IBM is a technology company specializing in computer hardware, software, and IT consulting. The company recently expanded its presence in cloud, AI technology, and services to better serve its clients when entering a new vertical. As an international, IBM has a presence in over 130 countries and operates in five segments: software, consulting, infrastructure, funding and others.
The company's latest financial issues reported $ 14.5 billion in sales for Q1'25, up 1% from the same quarter last year. Net income was also up 33% year -on -year, totaling $ 1.1 billion.
International Business Machines is an aristocrat dividend that has increased its dividends for 30 consecutive years. It pays on an annual dividend of $ 6.72 per share, converting to a product of approximately 2.30%. Finally, consensus among 20 analysts rate IBM modest purchase.
Barchart's views show that IBM is a “100%purchase,” with a general strength score of the maximum, and its current direction at its strongest levels. This is an exceptionally bullish signal, which shows peak momentum.
The last aristocrat dividend on this list is Abbott Laboratories – a company that I covered many times, so I'll keep the presentations brief. Abbott is a diverse healthcare provider that caters for a range of diseases and nutritional needs. As a world company, it has a presence in over 160 countries and more than 300 sub -companies worldwide.
Abbott Laboratories operates in five business segments: established pharmaceuticals, diagnostics, nutritional products, medical devices, and specialized products.
The company's latest financial issues reported that sales were around $ 10.4 billion, up 4% from the same period last year. Its net income also increased 8.2% year -on -year, to $ 1.33 billion.
Abbott Laboratories has increased its dividends for 53 years in a row and pays a current annual dividend of $ 2.36, converting to a product of around 1.77%. That said, 26 analysts rank the stock on average “strong purchase.”
Barchart's views show that ABT stock has an average of 88% purchase, with an average “current strength” and “address”. I've been watching this stock, and I've noticed that taking a profit has been happening. So, it could be a good opportunity to take advantage of the next bull run.
These three dividend aristocrats are quality names and reasonable choices for any income portfolio. And just because technical opinion says that buying doesn't mean you should. But if you believe in the techniques, a bull's run can be around the corner.
At the date of publication, Rick Orford had no jobs (either directly or indirectly) in any of the guarantees mentioned in this article. All the information and data in this article is for information purposes only. This article was originally published on Barchart.com
